Table 1.
Clinical characteristics of the patients treated with dalbavancin
| Patient # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| Age | 66 | 80 | 75 | 69 | 77 | 87 | 77 | 69 | 70 | 92 | 78 | 85 | 71 | 83 | 71 | 75 |
| Sex | M | M | M | M | F | M | F | F | M | M | F | F | F | M | F | M |
| Charlson | 2 | 5 | 2 | 3 | 3 | 7 | 3 | 3 | 3 | 5 | 3 | 7 | 5 | 7 | 3 | 4 |
| Infection | Early THAi | Ch TKAi | Ch THAi | UIPC (THA) | Dyaphisitis after G | Ch THAi | UIPC (TKA) | Ch THAi | Ch THAi septic pseudoarthrosis |
Ch TKAi | Ch THAi | Ch TKAi | Acute hem TKAi | Acute hem TKAi | Early TKAi | Acute hem TKAi (IE) |
| Surgery | 2SE AIAS |
2SE AIAS |
G | 2SE AIAS |
Drainage | G | NONE (supressive treatment) |
2SE AIAS |
2SE AIAS |
Drainage | 2SE AIAS |
Prosthesis removal & Arthrodesis | DAIR | Prosthesis removal AIAS |
2SE AIAS |
NONE (supressive tratment) |
| Aetiology | MSSA & CoNS | MSSA & MRSA | Ef | Ef | MSSA | Ef | CoNS | Se | Ef and Se | MRSA | Se | MRSA & Se | Se | Ef | MRSA | Efa |
| Reasons for DAL use | NOBCA | INT& TOX |
FOC | TOX | FOC | NOBCA | NOBCA | NOBCA | FOC | NOBCA | NOBCA | NOBCA | NOBCA & INT |
NOBCA & INT |
NOBCA & INT |
NOBCA |
| DAL dosing | 1g day 1 0.5g 10w |
1g day1 1g 8w |
1g day 1 1g 12w |
1g day 1 0.5g 8w |
1g day 1 0.5 g 6w |
1g day 1 0.5 g 6w |
LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | -1.5 g day 1 and day 7 -1.5 g biweekly fourmonths -Then 1.5 g monthly |
| Side effects | - | - | - | - | - | - | Leukopenia | - | - | - | - | Rash | - | - | - | - |
| Days of follow up since DAL stop | 498 | 777 | 647 | 592 | 540 | 542 | 422 | 447 | 467 | 94 | Clinical faliure | 508 | 70 | 350 | 313 | Ongoing |
| Outcome | C | C | C | C | C | C | Ongoing (Read text) |
C | C | Died (unrelated) |
Fa | C | F | C | C | Ongoing (read text) |
CoNS obtained from surgical samples showed clinical susceptibility after clinical failure. Ef: Enterococcus faecium, Efa: Enterococcus faecalis. IE: infective endocarditis, 2SE: 2 stage Exchange, AIAS: antibiotic impregnated articulated spacer, C: Cured, Ch: Chronic, CF: Clinical failure, CoNS: coagulase-negative staphylococci, INT: Interactions, FOC: Failure with other choices, G: Girdlestone, LDBD: Low dose biweekly DAL: 1.5 g. day1, 0.5 g. day7, then biweekly, NOBCA: No oral better choice available, Se: Staphylococcus epidermidis, THAi: Total hip arthroplasty infection, TKAi: Total knee arthroplasty infection, TOX: Toxicities, UIPC: unsuspected intraoperative positive cultures, W: weeks